Faculty Opinions recommendation of First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
2012 ◽
Vol 7
(9)
◽
pp. 1417-1422
◽